deucravacitinib

Showing 1 posts of 1 posts found.

Bristol Myers Squibb’s deucravacitinib beats Amgen’s Otezla to meet main goal in plaque psoriasis

November 4, 2020
Research and Development BMS, deucravacitinib, plaque psoriasis

Bristol Myers Squibb has unveiled new Phase 3 data showing that its oral, selective tyrosine kinase 2 (TYK2) inhibitor deucravacitinib …

Latest content